Macrophage heterogeneity in atrial remodeling
Macrophage heterogeneity in atrial remodeling
批准号:
10656427
负责人:
Maarten Hulsmans
金额:
$57.9万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-09-01 至 2026-07-31
关键词:
AddressAgeAnticoagulationArrhythmiaAtrial FibrillationAtrial FunctionAttenuatedBone MarrowBone Marrow TransplantationBrainCardiacCardiac OutputCardiac Surgery proceduresCardiovascular systemCellsClinicalCoagulation ProcessCollagenComplementComputational BiologyComputing MethodologiesDataData SetDepositionDeteriorationDiseaseEchocardiographyElderlyElectrophysiology (science)EndotheliumFibroblastsFibrosisGene DeletionGenerationsGenesGeneticGoalsGrowthHeartHeart AtriumHeart failureHeterogeneityHistologicHistologyHumanHypertensionImmunologyIn VitroIncidenceInflammatoryIntestinesKnock-outLaboratoriesLeftLeft Ventricular RemodelingLeft atrial structureLeukocytesMacrophageMapsMarrowMitral Valve InsufficiencyMusObesityOperative Surgical ProceduresOpticsOrganPathway interactionsPatientsPharmacologic SubstancePhenotypePlayPreparationPublishingResearchRestRisk FactorsRoleSamplingScienceSignal TransductionStrokeTestingTherapeuticTherapeutic EmbolizationTimeTissuesTransgenic MiceTransplantationVentricularWorkantagonistclinical riskclinically relevantcombatexperimental studygain of functionhemodynamicshuman diseaseimmunomodulatory therapiesin vivoinsightloss of functionmonocytemouse modelmultiphoton microscopynovelosteopontinpre-clinicalrecruitsecond harmonicsingle-cell RNA sequencingsmall moleculesource localizationtargeted treatmenttherapeutic evaluationtranslational goal
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Atrial remodeling, including dilation and fibrosis, can lead to hemodynamic deterioration and atrial fibrillation.
As a consequence, cardiac output declines and atrial clots embolize to the brain, intestines and other organs.
While valve surgery and anticoagulation therapy reduce heart failure and stroke, there are nevertheless
numerous patients who would benefit from a therapy inhibiting atrial remodeling and its consequences. To
address this urgent unmet clinical need, we here propose to investigate the role of macrophages, the fourth
most numerous cardiac cell, in atrial remodeling. In preliminary work for this application, i) we developed and
validated a new mouse model of atrial remodeling that combines key clinical risk factors, ii) we obtained single-
cell RNA-sequencing (scRNA-seq) data from the left atria of mice with atrial remodeling, iii) we determined the
ontogeny of atrial macrophages in the steady state and after atrial remodeling, and iv) we established a
pipeline for scRNA-seq of human left atrial tissues from patients with atrial disease undergoing heart surgery at
MGH. We now propose to test if macrophages form the atria's Achilles' heel promoting atrial remodeling,
fibrosis and atrial fibrillation. We will explore the role of macrophage subsets in atrial remodeling using genetic
and pharmaceutical cell depletion strategies. We hypothesize that during atrial remodeling, disease-promoting
macrophages are derived from blood monocytes while locally sourced macrophages are protective. In these
studies, we will profile structural remodeling of the left atrium by echocardiography, hemodynamic and
electrophysiological studies, histological analysis and FACS followed by real-time qPCR. Our preliminary
scRNA-seq data provide us with a wealth of potential targets to study the causal role of fibrosis-related
macrophage genes in atrial remodeling by loss- and gain-of-function studies. We will test the hypothesis that
gene deletion in bone marrow-derived cells, i.e. recruited macrophage subsets, attenuates atrial fibrosis by
cross-talk to fibroblasts and reduced collagen deposition, leading to less atrial remodeling and reduced
inducibility of atrial fibrillation. In a translational aim, we will study macrophage heterogeneity in human atrial
tissues by scRNA-seq. We will focus on the comparison between human and mouse scRNA-seq data sets
using state-of-the-art computational methods to steer the preclinical discovery work towards pathways that are
important in human disease. Our collaborative application unites an interdisciplinary team with expertise in
immunology, cardiovascular science and computational biology. While the novel research plan is ambitious, we
believe that our preliminary data demonstrate feasibility and provide us with a unique opportunity to study a
question with high clinical relevance.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Cardiac resident macrophages in AV node conduction
-
批准号:10365141
-
项目类别:
-
资助金额:$76.28万
-
财政年份:2021
-
负责人:Maarten Hulsmans
-
依托单位:
Macrophage heterogeneity in atrial remodeling
-
批准号:10470878
-
项目类别:
-
资助金额:$57.9万
-
财政年份:2021
-
负责人:Maarten Hulsmans
-
依托单位:
Cardiac resident macrophages in AV node conduction
-
批准号:10532806
-
项目类别:
-
资助金额:$72.45万
-
财政年份:2021
-
负责人:Maarten Hulsmans
-
依托单位:
Macrophage heterogeneity in atrial remodeling
-
批准号:10291930
-
项目类别:
-
资助金额:$58.74万
-
财政年份:2021
-
负责人:Maarten Hulsmans
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: